stocks logo

ABEO Earnings

Abeona Therapeutics Inc
$
6.560
+0.18(2.821%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

Earning Analysis

Welcome to our in-depth analysis of Abeona Therapeutics Inc(ABEO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Abeona Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
FY2024Q12024-05-15--0.47-0.53-12.77125.00K--+12.14+2.62
FY2023Q42024-03-18--0.51-0.64-25.49----19.00-11.82
FY2023Q32023-11-13--0.53-0.48+9.43---+10.02+2.44
FY2023Q22023-08-08--0.66-0.44+33.33-3.50M--+4.70
-2023-05-11--0.68-0.54+20.59----7.19-7.50
-2022-11-14--1.78-1.48+16.85----5.47-7.97
-2022-08-11--1.25-2.08-66.40---+12.02+10.58
-2022-05-13--0.08-0.10-25.00----+6.25
-2022-03-31--0.13-0.14-7.69---+3.23+6.45
-2021-05-18--0.19-0.17+10.53---+14.71+13.97

ABEO Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Abeona Therapeutics Inc reported performance for FY2024Q1, announced on 2024-05-15. The company achieved an EPS of -0.53, compared to analyst estimates of -0.47 by -12.77% . Revenue for the quarter reached 0.00 compared to expectations of 125.00K by % .
The stock price reacted with a 12.14% one-day change and a 2.62% five-day change following the earnings release. These movements reflect market reaction in Abeona Therapeutics Inc growth trajectory and strategic initiatives.

ABEO Earnings Forecast

Looking ahead, Abeona Therapeutics Inc(ABEO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 0.6%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted Go Up by 16.52% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Abeona Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between ABEO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.6%
In Past 3 Month
Revenue Estimates for Q2 2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+16.52%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
--
Revenue Estimate-Annual FY 2025:47.91M
--
EPS Estimate-Annual FY 2025:0
Stock Price6.56

ABEO Revenue and EPS Performance: A Historical Perspective

Abeona Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q1 (2024-05-15,):
EPS: -0.53 (Actual) vs.-0.47 (Estimate) (-12.77%)
Revenue: 0.00 (Actual) vs. 125.00K (Estimate) (%)
Price Reaction: 12.14%(1-Day), 2.62%(5-Day)
FY2023Q4 (2024-03-18,):
EPS: -0.64 (Actual) vs.-0.51 (Estimate) (-25.49%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -19.00%(1-Day), -11.82%(5-Day)
FY2023Q3 (2023-11-13,):
EPS: -0.48 (Actual) vs.-0.53 (Estimate) (9.43%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 10.02%(1-Day), 2.44%(5-Day)
Earnings Reaction
The chart below shows how ABEO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABEO sees a +3.59% change in stock price 10 days leading up to the earnings, and a +3.32% change 10 days following the report. On the earnings day itself, the stock moves by +2.05%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2024, the stock changed -2.34% on the day following the earnings release and then changed by -10.62% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

Transcript Summary

Abeona Therapeutics Inc (ABEO) Q1 2025 Earnings Call Summary
Positive
2025-05-17
The earnings call reveals positive developments, such as the PRV sale securing funding for two years, launch preparations for ZEVASKYN, and improved financial metrics with reduced net loss. The partnership with Ultragenyx and revenue potential of pz-cel also add to the optimism. However, uncertainties in patient numbers and cash position projections slightly temper enthusiasm. Overall, the strong funding position and strategic partnerships suggest a positive stock price movement.
Abeona Therapeutics Inc (ABEO) Q1 2025 Earnings Call Summary
Positive
2025-05-15
The earnings call reveals several positive aspects: the strategic partnership with Ultragenyx, a strong revenue potential for pz-cel, and a significant cash infusion from the PRV sale, which extends the funding runway. The reduced net loss and improved financial metrics further enhance the outlook. Despite some uncertainties in patient eligibility numbers and cash projections, the overall sentiment is positive, driven by strategic partnerships, financial improvements, and the upcoming launch of ZEVASKYN, indicating a likely stock price increase in the short term.
Abeona Therapeutics Inc (ABEO) Q1 2025 Earnings Call Summary
Positive
2025-05-15
The earnings call highlights a strong financial position bolstered by the PRV sale, which extends the runway to projected profitability. Despite a net loss, improved operational efficiencies are evident. The partnership with Ultragenyx and the upcoming PDUFA dates also indicate growth potential. Concerns about competition and patient access are noted, but the overall sentiment remains positive due to strategic partnerships, financial strength, and potential revenue from pz-cel.
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Summary
Negative
2025-03-22
The earnings call highlights several concerns: increased losses, competitive pressures, and financial risks without a shareholder return plan. While cash reserves have improved, the lack of clear guidance on managing manufacturing capacity and patient backlog raises uncertainties. The Q&A reveals management's evasive responses on critical issues, such as patient eligibility and backlog management, contributing to a negative sentiment. The absence of a shareholder return plan further dampens investor confidence, leading to an overall negative outlook for the stock price in the short term.
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Summary
Neutral
2025-03-20
The earnings call presents a mixed outlook. While there is potential revenue from pz-cel and a strong cash position, regulatory risks, supply chain challenges, and increased expenses raise concerns. The Q&A session highlighted management's inability to provide clear guidance on patient eligibility and education timelines, which adds uncertainty. Given these factors, the stock price is likely to remain neutral in the short term.

FAQ

arrow icon

What were the key highlights of ABEO’s latest earnings report for FY2024Q1?

ABEO reported its FY2024Q1 earnings on 2024-05-15, showcasing a revenue of 0.00 against an estimate of 125.00K, resulting in a 0% surprise. The EPS was -0.53, surpassing the expected -0.47 by -12.77% . The stock experienced a 12.14% price change on the earnings day and a 2.62% change over the next five days, reflecting market reactions to the results.
arrow icon

How did ABEO’s stock price react after the FY2024Q1 earnings release?

arrow icon

What are the revenue and EPS estimates for ABEO for undefined?

arrow icon

How does ABEO’s stock price correlate with earnings forecast revisions?

arrow icon

What should investors expect from ABEO’s next earnings report?

arrow icon

What is the sentiment in Abeona Therapeutics Inc (ABEO) Q1 2025 Earnings Call Summary?